April 11, 2025
By 2030, around 1.2 million people in the U.S. are expected to be living with Parkinson’s disease, which underscores the need for better early detection methods and personalized care.
Genetic testing is changing how we approach Parkinson’s disease. With the right tools, we can identify genetic markers that help us understand why the disease develops and how it progresses. This opens the door to earlier diagnosis and more tailored treatments, potentially even stopping the disease before it begins or slowing its progression.
In this blog, we’ll look at how genetic testing is shaping a more personalized, informed approach to managing Parkinson’s, offering new insights for researchers and healthcare professionals.
Parkinson's disease (PD) is a neurodegenerative disorder that affects motor control. It is characterized by the degeneration of dopamine-producing neurons in the substantia nigra, a region of the brain involved in movement regulation. This loss of dopamine leads to the hallmark symptoms of the disease, including tremors, rigidity, bradykinesia (slowness of movement), and postural instability.
Several genes are linked to PD, influencing its onset and progression in unique ways. These genes include SNCA, LRRK2, PARK7, PINK1, and GBA, each contributing to the disease in distinct ways.
The SNCA gene is responsible for producing alpha-synuclein, a protein that forms harmful clumps in the brain, known as Lewy bodies. These clumps disrupt normal brain cell function and are a key feature of Parkinson's disease, although they can also be found in Lewy body dementia. Mutations in SNCA can cause these clumps to form more quickly, leading to earlier onset and faster progression of the disease.
The LRRK2 gene is the most commonly mutated gene in familial Parkinson’s disease. It encodes for a protein involved in various cellular functions, including neuronal signaling and inflammation.
Mutations in LRRK2 lead to an overactive form of the LRRK2 protein, which disrupts normal cellular processes and causes the degeneration of dopaminergic neurons. While LRRK2 mutations are rare, they are one of the most significant genetic contributors to both familial and some sporadic (non-hereditary) forms of PD.
These genes help protect cells from damage by maintaining healthy mitochondria, the cell’s powerhouses. Mutations in PINK1 and PARK7 lead to a breakdown in mitochondrial function, contributing to the early onset of Parkinson’s—often before age 50.
The GBA gene encodes an enzyme involved in the breakdown of lipids within cells. Mutations in GBA can cause a deficiency of this enzyme, leading to the accumulation of certain lipids in brain cells. This buildup triggers inflammation and neurodegeneration, which contribute to Parkinson’s.
GBA mutations are considered one of the most common genetic risk factors for Parkinson’s, especially in individuals who develop the disease later in life.
Genetics alone doesn't determine whether someone will develop Parkinson's; other factors play a role too. How PD manifests can vary, even among people with the same mutations.
Mutations in genes like SNCA and LRRK2 can be passed down in families, making some people more likely to develop Parkinson's. But not everyone with these mutations gets the disease. This highlights how complex PD is—genetics are just one piece of the puzzle.
Some genetic mutations, like those in PINK1 and PARK7, lead to Parkinson's earlier in life, while others, like LRRK2, tend to cause the disease later on. But even with the same mutation, the age at which symptoms show up can differ based on a mix of other genetic and environmental factors.
Environmental factors, such as exposure to toxins or head injuries, can trigger Parkinson’s in genetically predisposed people. For example, someone with an LRRK2 mutation might have a higher chance of developing the disease if they live in an area with high pesticide use.
Genetic testing can provide important information for managing Parkinson's, especially when it comes to treatment and lifestyle choices. However, while it can give clues about risk, it doesn’t guarantee that someone will or won’t develop the disease. Still, knowing about these genetic risks helps patients make more informed decisions and gives researchers a better chance of creating targeted therapies.
In conclusion, genetic factors are a key part of Parkinson's, but they don't tell the whole story. They interact with other genes, environmental exposures, and random events that shape how the disease develops.
Genetic testing plays a crucial role in managing Parkinson's disease. Here’s why it matters and how it can shape treatment and outcomes:
Understanding your genetic risk gives you a head start. If you have a family history or known genetic mutations linked to Parkinson’s, genetic testing can detect the risk even before symptoms appear. Early detection means you can start monitoring your health sooner, which could delay disease progression and help manage symptoms more effectively.
With genetic test results, doctors can make smarter treatment choices. Certain gene mutations, like LRRK2 or PINK1, affect how the disease develops and how it responds to treatment. By knowing a patient’s genetic profile, healthcare providers can select therapies that are more likely to work and avoid trial-and-error approaches that waste time and resources.
Knowing the genetic cause of Parkinson’s allows treatments to be tailored to each person. Rather than just masking symptoms, doctors can address the disease’s root causes. This personalized approach increases the chances of slowing down the disease and improving overall quality of life.
Genetic testing can help identify individuals at risk, even before symptoms appear. For example, those with mutations like GBA might not show signs of Parkinson’s until later in life. But with early testing, they can start planning for monitoring and early interventions, potentially slowing or even preventing symptoms from becoming severe.
Genetic testing opens up more targeted treatment options. For example:
Knowledge of genetic mutations helps tailor treatment plans:
Genetic testing is crucial for diagnosing and managing Parkinson’s disease (PD), but it comes with challenges. With both clinical genetic tests and direct-to-consumer (DTC) options available, interpreting the results can be tricky. The complexity of Parkinson’s genetics means that no single test can offer a complete picture.
However, DTC tests, while convenient, often miss key mutations and offer limited analysis, leaving gaps in understanding and potential confusion for patients.
Some with genetic mutations may never show symptoms, while others without clear genetic risks may develop Parkinson’s. This highlights the need for clinical genetic tests, which offer more comprehensive data and professional counseling to help patients understand their results.
Given these challenges, clinical genetic tests are more reliable and provide a clearer picture than DTC tests. Clinical tests look at a broader set of genetic markers and come with genetic counseling to help patients understand their results. This guidance is crucial for making informed decisions about treatment and managing Parkinson’s effectively.
To overcome the limitations of DTC tests and provide more accurate, clinically relevant genetic testing, the PD GENEration program, launched by the Michael J. Fox Foundation, offers free genetic testing for individuals with Parkinson’s disease.
Clinical genetic tests, like those from PD GENEration, offer more detailed insights than DTC tests, guiding treatment and improving outcomes. PD GENEration provides free genetic testing and counseling, making it accessible to all Parkinson’s patients.
Genetic testing plays a critical role in understanding Parkinson's disease (PD), but as seen through the real-life case scenarios, it’s clear that genetics alone don’t tell the whole story.
For example, take the case of Michael J Fox. He was diagnosed at just 29, a rare age for the disease. His diagnosis was particularly unexpected because there wasn’t a clear genetic history in his family, nor was he carrying known mutations like LRRK2 or SNCA that are often associated with early-onset Parkinson’s.
Fox’s case challenges the idea that Parkinson’s is purely genetic. He has since become an advocate for Parkinson’s research, particularly focused on identifying both genetic and environmental factors that contribute to the disease.
Fox’s situation highlights that while genetic testing is crucial for identifying certain risk factors, it doesn’t provide a complete answer. His case suggests that environmental factors, lifestyle choices, and perhaps even the interaction between various genes contribute to his Parkinson's, beyond just an inherited mutation.
Whereas Muhammad Ali, the legendary boxer, was diagnosed with Parkinson’s later in life, but his case was linked more to his career in boxing than to any genetic mutation. Ali had been hit in the head repeatedly throughout his career, and research has shown that repeated head trauma increases the risk of developing neurodegenerative diseases like Parkinson’s.
Genetic testing in Ali’s case would likely not have revealed any major genetic mutations linked to Parkinson’s. Instead, his Parkinson's was likely a result of environmental factors—specifically, brain injuries sustained over years of boxing.
This case underscores a crucial point: genetic predisposition is only part of the equation. In some individuals, environmental factors like trauma or exposure to toxins can be the driving force behind the development of Parkinson’s, irrespective of genetic mutations. Ali’s story is a reminder that genetic testing should be just one tool in understanding the disease, not the definitive answer.
Genetic testing is an essential tool in the fight against Parkinson’s disease, but it isn’t a silver bullet. The PD GENEration study found that 13% of participants had genetic variants that could increase their risk of Parkinson's.
Among those with high-risk factors, such as early-onset Parkinson’s or a family history, 18% had these variants. Surprisingly, 9% of people without any high-risk factors also had these genetic variations.
Genetic testing helps identify those at risk and guides treatment decisions, but it must be viewed as part of a broader approach to understanding and managing the disease. The future of Parkinson’s care will likely be built on combining genetic insights with environmental and lifestyle factors to create more effective, personalized treatments.
Genetic testing plays a vital role in understanding Parkinson’s disease and guiding personalized treatments. As genetic insights grow, so do opportunities for targeted therapies that cater to individual needs. With programs like PD GENEration providing accessible genetic testing and counseling, patients can take proactive steps in managing their condition.
If you’re looking to advance your research, Biostate AI offers affordable, comprehensive RNA sequencing services. Whether you're studying longitudinal changes, multi-organ impacts, or individual differences, Biostate AI’s Total RNASeq solutions, starting at just $80/sample, provide critical insights with less effort and cost.
Get a Quote today and accelerate your research with Biostate AI.
